Alpha-1-Antitrypsin Deficiency Registry Study Group.
What does A1A stand for?
A1A stands for Alpha-1-Antitrypsin
This definition appears frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
- A1 blockade at reperfusion
- alfentanil 10 micrograms/kg
- aminophylline 10 mg/kg
- Anchorage Terminal Radar Approach Control
- Africanization (A followed by 12 letters, followed by N)
- A13 dopamine cell group
- administration of 125I
- Aging at 150 degrees C
- A to G transition at position 1555
- Auto One Acceptance Corporation
- Alpha-1 Antitrypsin Deficiency (aka AAT deficiency)
- Alpha-1 Adrenergic Receptor
- ligand-A1 Adenosine Receptor
- Alpha-1 Anti-Trypsin
- Alpha-1 Brain Globulin
- Airman First Class
- Glycated Hemoglobin [not an acronym - average blood glucose control over 2-3 months]
- Angiotensin-1-Converting Enzyme (plasma concentration)
- Alpha-1 Globulin
Samples in periodicals archive:
This first genetic test for Alpha-1-Antitrypsin (AAT) will detect genetic abnormalities associated with adult emphysema and progressive liver cirrhosis in children.
Studies have demonstrated that monthly administration of the substance significantly increases the level of alpha-1-antitrypsin in the blood and lungs.
Koczulla's project, "Quantification of Alpha-1-Antitrypsin in Exhaled Breath Condensate of Patients with Alpha-1-Antitrypsin Deficiency, Smokers, and COPD Patients," intends to create a non-invasive tool to measure Alpha-1-Antitrypsin levels, examine correlations with markers of pulmonary inflammation, and ultimately help guide disease therapy.
Alpha-1 is a form of congenital emphysema that causes degradation of a patient's lung tissue due to inadequate production of alpha-1-antitrypsin (AAT).
For many people with rare illnesses such as lysosomal storage disease, hemophilia, Guillain-Barre syndrome, and Alpha-1-antitrypsin deficiency disease, specialty pharmaceuticals represent their standard of care, keeping symptoms stable and helping to reclaim quality of life.
The cartridges use affinity-purified polyclonal antibodies to remove more than 98 percent of the six most abundant proteins (albumin, immunoglobulin G, immunoglobulin A, alpha-1-antitrypsin, transferrin and haptoglobin) in human serum and the three most abundant proteins (albumin, immunoglobulin G and transferrin) in mouse serum, with minimal non-specific removal of other proteins.
As published in the March issue of Cell Transplantation, Geron scientists describe protocols that differentiate hESCs into human hepatocytes that express albumin, alpha-1-antitrypsin, glycogen and toxicity studies to be performed earlier in the drug discovery process, enabling the elimination of toxic compounds before undertaking costly human trials.